Regeneron Pharmaceuticals was downgraded from Buy to Hold by Brean Capital one week ago. Regeneron Pharmaceuticals shares are selling at $176.16, 0.8% above the $174.84 price point of one week ago.
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders.
Regeneron Pharmaceuticals has overhead space with shares priced $176.30, or 3.2% below the average consensus analyst price target of $182.08. The stock should find initial support at its 50-day moving average (MA) of $173.36 and further support at its 200-day MA of $144.73.
In the past 52 weeks, shares of Regeneron Pharmaceuticals have traded between a low of $42.83 and a high of $188.95 and are now at $176.30, which is 312% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 0.9% while the 200-day MA has risen 0.4%.